PL2707017T3 - Liksisenatyd i metformina do leczenia cukrzycy typu 2 - Google Patents
Liksisenatyd i metformina do leczenia cukrzycy typu 2Info
- Publication number
- PL2707017T3 PL2707017T3 PL12723132T PL12723132T PL2707017T3 PL 2707017 T3 PL2707017 T3 PL 2707017T3 PL 12723132 T PL12723132 T PL 12723132T PL 12723132 T PL12723132 T PL 12723132T PL 2707017 T3 PL2707017 T3 PL 2707017T3
- Authority
- PL
- Poland
- Prior art keywords
- lixisenatide
- metformin
- treatment
- diabetes type
- diabetes
- Prior art date
Links
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
- 229960001093 lixisenatide Drugs 0.000 title 1
- 108010004367 lixisenatide Proteins 0.000 title 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
- 229960003105 metformin Drugs 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166120 | 2011-05-13 | ||
| EP12163637 | 2012-04-10 | ||
| PCT/EP2012/058747 WO2012156298A1 (en) | 2011-05-13 | 2012-05-11 | Lixisenatide and metformin for treatment of diabetes type 2 |
| EP12723132.2A EP2707017B1 (en) | 2011-05-13 | 2012-05-11 | Lixisenatide and metformin for treatment of diabetes type 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2707017T3 true PL2707017T3 (pl) | 2016-03-31 |
Family
ID=46148833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12723132T PL2707017T3 (pl) | 2011-05-13 | 2012-05-11 | Liksisenatyd i metformina do leczenia cukrzycy typu 2 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20130065828A1 (pl) |
| EP (1) | EP2707017B1 (pl) |
| JP (2) | JP6442284B2 (pl) |
| KR (1) | KR20140043755A (pl) |
| CN (2) | CN107693782A (pl) |
| AU (1) | AU2012257849B2 (pl) |
| BR (1) | BR112013029062A2 (pl) |
| CA (1) | CA2835259C (pl) |
| CY (1) | CY1117250T1 (pl) |
| DK (1) | DK2707017T3 (pl) |
| ES (1) | ES2556466T3 (pl) |
| HR (1) | HRP20151369T1 (pl) |
| HU (1) | HUE028459T2 (pl) |
| MX (1) | MX362527B (pl) |
| PL (1) | PL2707017T3 (pl) |
| PT (1) | PT2707017E (pl) |
| RU (1) | RU2623023C2 (pl) |
| SI (1) | SI2707017T1 (pl) |
| WO (1) | WO2012156298A1 (pl) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
| SG10201403840VA (en) | 2009-07-06 | 2014-10-30 | Sanofi Aventis Deutschland | Aqueous insulin preparations containing methionine |
| SI2498802T1 (sl) | 2009-11-13 | 2015-05-29 | Sanofi-Aventis Deutschland Gmbh | Farmacevtski sestavek, ki vsebuje agonist GLP-1, inzulin in metionin |
| PL2498801T3 (pl) | 2009-11-13 | 2018-08-31 | Sanofi Aventis Deutschland | Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę |
| BR112013004756B1 (pt) | 2010-08-30 | 2020-04-28 | Sanofi Aventis Deutschland | uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CA2846413C (en) | 2011-08-29 | 2021-11-02 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| EP3091965A1 (en) | 2014-01-09 | 2016-11-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| CA2932877A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| RU2016132340A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулина аспарта |
| TWI758239B (zh) | 2014-12-12 | 2022-03-21 | 德商賽諾菲阿凡提斯德意志有限公司 | 甘精胰島素/利司那肽固定比率配製劑 |
| US20160235818A1 (en) * | 2015-01-16 | 2016-08-18 | Sanofi-Aventis Deutschland Gmbh | Treatment of Pediatric Type 2 Diabetes Mellitus Patients |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| JP2021530544A (ja) * | 2018-07-23 | 2021-11-11 | イーライ リリー アンド カンパニー | 糖尿病のためのｇｉｐ／ｇｌｐ１共アゴニストを使用する方法 |
| CN119296436A (zh) | 2019-12-19 | 2025-01-10 | 奥弗莱克斯美国有限责任公司 | 用于标记和标识的标识标签 |
| TW202228762A (zh) | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| CA2573856A1 (en) * | 2004-08-03 | 2006-02-16 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
| CN101291685A (zh) * | 2005-08-19 | 2008-10-22 | 安米林药品公司 | 治疗糖尿病和降低体重的毒蜥外泌肽 |
| AU2007284365A1 (en) * | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| KR20160143897A (ko) * | 2009-02-13 | 2016-12-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제 |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| ES2553593T3 (es) | 2009-11-13 | 2015-12-10 | Sanofi-Aventis Deutschland Gmbh | Lixisenatida como complemento de la metformina en el tratamiento de la diabetes tipo 2 |
-
2012
- 2012-05-11 HR HRP20151369TT patent/HRP20151369T1/hr unknown
- 2012-05-11 CN CN201711058028.0A patent/CN107693782A/zh active Pending
- 2012-05-11 KR KR1020137033310A patent/KR20140043755A/ko not_active Ceased
- 2012-05-11 US US13/469,633 patent/US20130065828A1/en not_active Abandoned
- 2012-05-11 CN CN201280034737.4A patent/CN103841988A/zh active Pending
- 2012-05-11 RU RU2013155474A patent/RU2623023C2/ru active
- 2012-05-11 PT PT127231322T patent/PT2707017E/pt unknown
- 2012-05-11 DK DK12723132.2T patent/DK2707017T3/en active
- 2012-05-11 AU AU2012257849A patent/AU2012257849B2/en active Active
- 2012-05-11 BR BR112013029062A patent/BR112013029062A2/pt not_active Application Discontinuation
- 2012-05-11 SI SI201230377T patent/SI2707017T1/sl unknown
- 2012-05-11 HU HUE12723132A patent/HUE028459T2/en unknown
- 2012-05-11 PL PL12723132T patent/PL2707017T3/pl unknown
- 2012-05-11 MX MX2013013307A patent/MX362527B/es active IP Right Grant
- 2012-05-11 CA CA2835259A patent/CA2835259C/en active Active
- 2012-05-11 WO PCT/EP2012/058747 patent/WO2012156298A1/en not_active Ceased
- 2012-05-11 JP JP2014509752A patent/JP6442284B2/ja active Active
- 2012-05-11 ES ES12723132.2T patent/ES2556466T3/es active Active
- 2012-05-11 EP EP12723132.2A patent/EP2707017B1/en not_active Revoked
-
2015
- 2015-12-15 CY CY20151101144T patent/CY1117250T1/el unknown
-
2018
- 2018-07-20 JP JP2018136356A patent/JP6676108B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1194307A1 (en) | 2014-10-17 |
| HRP20151369T1 (hr) | 2016-01-15 |
| CY1117250T1 (el) | 2017-04-05 |
| ES2556466T3 (es) | 2016-01-18 |
| BR112013029062A2 (pt) | 2016-11-29 |
| RU2013155474A (ru) | 2015-06-20 |
| WO2012156298A1 (en) | 2012-11-22 |
| RU2623023C2 (ru) | 2017-06-21 |
| HUE028459T2 (en) | 2016-12-28 |
| KR20140043755A (ko) | 2014-04-10 |
| CN103841988A (zh) | 2014-06-04 |
| PT2707017E (pt) | 2016-01-12 |
| CA2835259A1 (en) | 2012-11-22 |
| JP6676108B2 (ja) | 2020-04-08 |
| MX2013013307A (es) | 2014-03-12 |
| SI2707017T1 (sl) | 2016-01-29 |
| JP6442284B2 (ja) | 2018-12-19 |
| MX362527B (es) | 2019-01-23 |
| JP2014514356A (ja) | 2014-06-19 |
| EP2707017B1 (en) | 2015-09-16 |
| EP2707017A1 (en) | 2014-03-19 |
| JP2018184441A (ja) | 2018-11-22 |
| CN107693782A (zh) | 2018-02-16 |
| DK2707017T3 (en) | 2016-01-04 |
| US20130065828A1 (en) | 2013-03-14 |
| AU2012257849B2 (en) | 2017-03-30 |
| CA2835259C (en) | 2020-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2707017T1 (sl) | Liksisenatid in metformin za zdravljenje sladkorne bolezni tipa 2 | |
| IL232251A0 (en) | Protocol for the treatment of type 2 diabetes | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| IL252699A0 (en) | Use of lequinimod to treat multiple sclerosis | |
| SMT202200266T1 (it) | Co-agonisti di glucagone e glp-1 per il trattamento dell'obesità | |
| PL2683395T3 (pl) | Zastosowanie małych dawek il-2 do leczenia cukrzycy typu 1 | |
| IL220889A0 (en) | Methods of treating diabetes with dll4 antagonists | |
| IL223289A0 (en) | Treatment of type 2 diabetes | |
| GB201000916D0 (en) | Treatment of biofilms | |
| EP2867239A4 (en) | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | |
| AP2013007179A0 (en) | Glycoside derivatives and their uses for the treatment of diabetes | |
| HUE038787T2 (hu) | Tripeptid készítmények és alkalmazásuk diabétesz kezelésére | |
| SG11201408717XA (en) | Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus | |
| EP2774917A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | |
| ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
| PH12014501052A1 (en) | Methods and compositions for the treatment of diabetes and related symptoms | |
| EP2402342A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES | |
| ZA201404738B (en) | Treatment of type i and type ii diabetes | |
| EP2680846A4 (en) | USE OF N- (4-METHOXYPHENYL) -1-PHENYL-1H-PYRAZOL-3-AMINE AND COMPOUNDS ASSOCIATED THEREWITH | |
| GB0919603D0 (en) | Use of thymosin beta-4 for treatment of type II diabetes | |
| EG27140A (en) | Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes | |
| PT2717872T (pt) | Combinação sinérgica para o tratamento da diabetes mellitus tipo 2 | |
| IL232294B (en) | Preparations for the treatment of diabetes |